Novo Integrated Sciences, Inc.: Nasdaq/NYSE listing notice — Novo Integrated Sciences receives Nasdaq delisting notice for late Q2 FY2023 filing

April 20, 2023, the Company received a notice (the “April Nasdaq Notice”) from Nasdaq advising the Company that it was not in compliance with Nasdaq’s continued listing requirements under the Rule as a result of its failure to timely file its Quarterly Report on Form 10-Q for the fiscal quarter ended February 28, 2023 (the “February Form 10-Q”). Because the November Form 10-Q remains unfiled, any additional Staff exception to allow the Company to regain compliance with the Rule for all delinquent filings will be limited to a maximum of 180 days from the due date of the initial delinquent filin

January 25, 2023 from Nasdaq advising the Company that it was not in compliance with Nasdaq’s continued listing requirements under the Rule as a result of its failure to timely file the Form 10-K (which has since been filed) and its Quarterly Report on Form 10-Q for the fiscal quarter ended November 30, 2022 (the “November Form 10-Q”). Per the January Nasdaq Notice and in accordance with the December Nasdaq Notice, the Company had 60 calendar days from receipt of the December Nasdaq Notice or until February 13, 2023, to submit a plan to regain compliance with the Rule with the respect to the F